



US CHINESE ANTI-CANCER ASSOCIATION  
美中抗癌协会



东方临床肿瘤研究中心  
East Clinical Center of Oncology



Chinese Society of Clinical Oncology  
Beijing Xisike Clinical Oncology Research Foundation

# Simulation of Phase 1 Trial Design ALK inhibitor

Li Yan



# ALK inhibitor PF-06463922

- PF-06463922 is a selective, ATP-competitive small molecule tyrosine kinase inhibitor of the ALK and ROS1 (c-ROS oncogene 1) receptor tyrosine kinases (RTK) that also **potently inhibits ALK kinase domain mutations responsible for resistance to crizotinib.**
- Oncogenic fusions of ALK and ROS1 define two distinct subsets of human lung adenocarcinoma patients and play essential roles in regulation of tumor cell survival, growth and metastasis.

